VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
SANA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
SANASana Biotechnology, Inc.
$1.85$515M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. SANA
  4. Financial Ratios

Sana Biotechnology, Inc. (SANA) Financial Ratios

Latest Ratios: P/E Ratio -3.8x · EV/EBITDA N/A · ROE -118.7%. (2018–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

SANA Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Market Cap$515M$1.0B$376M$794M$744M$2.6B———
Enterprise Value$522M$1.0B$343M$764M$675M$2.4B———
P/E Ratio →-3.83————————
P/S Ratio—————————
P/B Ratio2.916.411.502.761.493.54———
P/FCF—————————
P/OCF—————————

P/E links to full P/E history page with 30-year chart

SANA EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
EV / Revenue—————————
EV / EBITDA—————————
EV / EBIT—————————
EV / FCF—————————

SANA Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Gross Margin—————————
Operating Margin—————————
Net Profit Margin—————————

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
ROE-118.7%-118.7%-99.2%-72.0%-43.9%-231.6%———
ROA-53.2%-53.2%-50.0%-40.8%-27.6%-38.3%-49.8%-58.2%-38.6%
ROIC-74.4%-74.4%-86.1%-63.8%-40.2%-476.6%———
ROCE-48.1%-48.1%-57.0%-48.4%-31.3%-41.3%-29.4%-65.9%-25.3%

SANA Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Debt / Equity0.490.490.380.360.220.15———
Debt / EBITDA—————————
Net Debt / Equity—0.04-0.13-0.10-0.14-0.20———
Net Debt / EBITDA—————————
Debt / FCF—————————
Interest Coverage—————————

SANA Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Current Ratio1.891.893.543.313.995.6212.227.4718.26
Quick Ratio1.891.893.543.313.995.6212.227.4718.26
Cash Ratio1.761.763.363.183.805.5512.037.1917.16
Asset Turnover—————————
Inventory Turnover—————————
Days Sales Outstanding—————————

SANA Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Dividend Yield—————————
Payout Ratio—————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Earnings Yield—————————
FCF Yield—————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%———
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%———
Shares Outstanding—$253M$231M$195M$188M$166M$188M$187M$187M

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Cash runway and dilution risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Book Value Premium Despite Pre-Revenue Status

Based on reported figures, SANA trades at 3.18 times book value with negative trailing earnings of -4.18 times P/E, a combination that signals investors are pricing pipeline optionality rather than current earnings power relative to clinical-stage peers.

A price-to-book of 3.18 for a company with negative returns on equity of -118.7% suggests the market is ascribing substantial value to clinical programs that are not yet reflected in book equity. Because goodwill of roughly $140.6 million forms a large share of book value, the multiple may be more sensitive to impairment risk than the headline figure implies. Investors should monitor whether the premium narrows as clinical milestones are reached or compresses if financing terms weaken.

Leverage Ratios Mask Thinning Equity Base

As reported in financial statements, SANA's debt-to-equity ratio of 0.30 in 2026Q3 appears moderate, but it rose from 0.63 in 2026Q1 only as equity eroded, indicating that the apparent deleveraging reflects a shrinking denominator rather than debt reduction.

The move in debt-to-equity over recent quarters appears driven more by equity loss from operating losses than by any change in the debt load, which may indicate a balance sheet becoming less resilient over time. Interest coverage is not meaningful given the absence of operating earnings, so debt service capacity depends entirely on access to external capital. This suggests refinancing or covenant risk warrants further investigation as cash reserves decline.

Current Ratio Flatters a Burn-Constrained Position

According to recent SEC filings, SANA's current ratio of 1.77 and quick ratio of 1.77 in 2026Q3 look comfortable, yet cash of $41.1 million against recurring operating outflows above $30 million per quarter implies only a few quarters of coverage.

With no inventory dependence, the quick and current ratios are identical and reflect short-term assets dominated by cash and investments that are being consumed quickly. The headline liquidity ratio therefore overstates the buffer relative to the burn rate. Under severe stress, a delayed financing could leave limited room before operations would need to be scaled back.

Working Capital Metrics Largely Unavailable

Based on reported figures, SANA's receivables, inventory, and payables cycle metrics are largely unavailable across the ten-quarter window apart from a single 71-day figure in 2026Q1, leaving cash conversion analysis limited.

Given the pre-revenue profile, asset turnover and days-sales metrics carry little analytical weight, and the data gap should not be read as evidence of operational inefficiency. The most informative efficiency signal is instead the decline in total assets and net PP&E, which may reflect a deliberate reduction in fixed-asset commitments. Investors should treat cash burn per program as the more relevant capital-efficiency measure.

Return Metrics Mislead on a Cash-Burning Platform

Based on reported figures, the most commonly misapplied ratio here is return on equity, where SANA's -118.7% reading reflects a shrinking equity base and operating losses rather than a durable measure of value destruction per dollar invested.

Return on equity is typically applied to profitable operating businesses, and for a clinical-stage biotech with minimal revenue it mainly reflects the size of the equity cushion relative to losses. A better lens is cash runway in quarters, combined with the probability-weighted value of each clinical program. This suggests the ratio should be read as a signal of financing dependence rather than a judgment on managerial returns.

Download Financial Ratios Data

Includes 30+ ratios · 8 years · Updated daily

Consensus & Technical Research Suite
Open SANA Terminal

SANA Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

SANA — Frequently Asked Questions

Quick answers to the most common questions about buying SANA stock.

What is Sana Biotechnology, Inc.'s P/E ratio?

Sana Biotechnology, Inc.'s current P/E ratio is -3.8x. This places it at the 50th percentile of its historical range.

What is Sana Biotechnology, Inc.'s ROE?

Sana Biotechnology, Inc.'s return on equity (ROE) is -118.7%. The historical average is -113.1%.

Is SANA stock overvalued?

Based on historical data, Sana Biotechnology, Inc. is trading at a P/E of -3.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.